ArticleHaematologica2022

Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin.

Chen Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.